-
2019.12.16
Ethical Drugs
- Notification of marketing of HARUROPI® TAPE in Japan (Transdermal, Parkinson’s disease treatment patch, development code: HP-3000)
-
2019.11.26
Research and Development
- Notification of the results of Phase II clinical study of HP-5000 in the U.S. (Transdermal, pain relief and anti-inflammatory patch)
-
2019.11.12
lR Information
- Notice regarding Cancellation of Treasury Shares
-
2019.10.28
Other
- Notice regarding Support for The Disaster of Typhoon No. 19 in 2019
-
2019.10.15
Research and Development
- Notification of FDA approval for SECUADO® in the U.S. (Transdermal, schizophrenia treatment patch, development code: HP-3070)
-
2019.10.10
lR Information
- FY02/2020 Q2 Results Earnings Release Presentation
-
2019.10.01
lR Information
- Notice regarding Results and Completion of Acquisition of Treasury Shares (Acquisition of treasury shares in accordance with the provisions of the Articles of Incorporation pursuant to Article 165, Paragraph 2 of the Companies Act)
-
2019.09.20
Research and Development
- Notification of approval for manufacturing and marketing approval of HARUROPI® TAPE in Japan (Transdermal, Parkinson’s disease treatment patch, development code: HP-3000)
-
2019.09.06
Other
- Notice regarding Support for The Disaster of The Torrential Rains in August 2019
-
2019.08.29
Research and Development
- Notification of application for manufacturing and marketing approval of the additional indications of opioid analgesic naive cancer pain relief of FENTOS® TAPE (Transdermal, pain management patch,Development code: HFT-290) in Japan
-
2019.07.26
lR Information
- Notice regarding Determination of Details of Issuance of Stock Compensation-Type Share Options (Stock Acquisition Rights)
-
2019.07.10
lR Information
- FY02/2020 Q1 Results Earnings Release Presentation
-
2019.07.10
lR Information
- Notice regarding Decision on Matters Relating to Acquisition of Treasury Shares and Cancellation of Treasury Shares
-
2019.07.10
lR Information
- Notice regarding Issuance of Stock Compensation-Type Share Options
-
2019.06.03
Ethical Drugs
- Notification of Transfer of Marketing and Manufacturing Approval and Distribution Rights for the transdermal follicle and luteinizing hormone product “Menoaid® Combipatch”
-
2019.05.24
Research and Development
- Notification of the results of the Phase II clinical study of HP-5070 in Japan (a transdermal drug for the treatment of primary local hyperhidrosis)
-
2019.05.24
Research and Development
- Notification of the results of Phase III clinical study of HP-3150 in Japan for “cancer pain” (an analgesic transdermal drug containing NSAIDs)
-
2019.05.24
lR Information
- Approach to and Policy on Reduction of Investment Unit, etc. 1.
-
2019.05.23
Management and Personnel
- Executive Appointments
-
2019.05.17
Other
- Salonpas® Named the World’s No. 1 OTC Topical Analgesic Patch Brand for the Third Consecutive Year
-
2019.04.26
Other
- Notice regarding Name Change in Mail-Order Business
-
2019.04.10
lR Information
- FY02/2019 Q4 Results Earnings Release Presentation
-
2019.04.10
Management and Personnel
- Executive Appointments
-
2019.03.01
Subsidiaries and Affiliated Companies
- Notification of a Subsidiary’s Share Transfer
-
2019.02.05
- Hisamitsu Pharmaceutical and Kyowa Hakko Kirin sign Commercialization Agreement for HP-3000, a Potential New Transdermal Patch for Parkinson’s Disease in Japan
-
2019.01.11
- FY02/2019 Q3 Results Earnings Release Presentation
